This contrasts to two recently published meta-analyses in which the use of SGLT2 inhibitors was associated with lower mortality and a lower risk of HF compared with dipeptidyl peptidase 4 inhibitors [100, 101]. This evidence concerns the gene SLC5A2 and hydrops fetalis.